also news on ARQ 531. Also institutional activity-1 sell several buys. IMO ARQL is a strong buy. Phase III results from liver cancer treatment will be released in March 2017. Pfizer bought 4.4% of ARQL shares earlier this year.
Posted by Hossein Forouzandeh on Nov 28th, 2016 // No Comments
ArQule logoAlgert Global LLC lowered its position in ArQule Inc. (NASDAQ:ARQL) by 10.9% during the third quarter, Holdings Channel reports. The institutional investor owned 121,292 shares of the company’s stock after selling 14,788 shares during the period. Algert Global LLC owned about 0.17% of ArQule worth $217,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Bridgeway Capital Management Inc. increased its stake in ArQule by 1.8% in the second quarter. Bridgeway Capital Management Inc. now owns 360,193 shares of the company’s stock worth $684,000 after buying an additional 6,200 shares in the last quarter. BlackRock Fund Advisors increased its stake in ArQule by 11.3% in the second quarter. BlackRock Fund Advisors now owns 162,541 shares of the company’s stock worth $309,000 after buying an additional 16,467 shares in the last quarter. Vanguard Group Inc. increased its stake in ArQule by 10.6% in the second quarter. Vanguard Group Inc. now owns 2,960,487 shares of the company’s stock worth $5,625,000 after buying an additional 282,734 shares in the last quarter. Bank of New York Mellon Corp increased its stake in ArQule by 2.5% in the second quarter. Bank of New York Mellon Corp now owns 87,710 shares of the company’s stock worth $167,000 after buying an additional 2,160 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in ArQule by 5.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 277,729 shares of the company’s stock worth $444,000 after buying an additional 13,979 shares in the last quarter. 58.10% of the stock is owned by institutional investors.
